CPP-ELP-H1

CPP-ELP-H1 (also known as Bac-ELP1-H1) is a thermally responsive polypeptide therapeutic designed for targeted cancer therapy, specifically breast cancer and glioblastoma. Developed by the University of Mississippi Medical Center and its spinout Thermally Targeted Therapeutics, the molecule is a fusion construct consisting of three functional domains: a cell-penetrating peptide (CPP, specifically the Bac peptide) to facilitate cellular and blood-brain barrier penetration, a thermally responsive elastin-like polypeptide (ELP) carrier, and a therapeutic peptide (H1) derived from helix 1 of the helix-loop-helix region of c-Myc. The ELP carrier remains soluble at normal body temperature but undergoes a phase transition to form aggregates when mild local hyperthermia is applied to the tumor site, enabling physical targeting and accumulation. Once inside the cancer cells, the H1 peptide blocks the transcriptional activity of the oncogenic protein c-Myc, thereby inhibiting tumor cell proliferation and inducing apoptosis.

Other names

Bac-ELP-H1Bac-ELP-H-1Bac-ELP-H 1BacELP1-H1BacELP-1-H1BacELP 1-H1cell penetrating peptide-elastin-like polypeptide-H1